Company Monitoring Page for Novo-Nordisk

latest headlines for company on cafepharma

Weight loss gold rush: Developers vie for next blockbuster treatment
Pharmaphorum
Tue, 10/8/24 - 09:45 am
Tags:
R&D, obesity, weight loss, Novo Nordisk, Eli Lilly, Roche, Boehringer Ingelheim
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
Fierce Pharma
Mon, 10/7/24 - 09:56 pm
Tags:
Mylan Labs, Natco, Novo Nordisk, Ozempic, generics, patents, legal
Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds
Pharma Voice
Mon, 10/7/24 - 11:23 am
Tags:
Novo Nordisk, Wegovy, cardiovascular disease, artificial intelligence, Dandelion Health
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Reuters
Thu, 10/3/24 - 11:47 am
Tags:
Novo Nordisk, logistics, labor strike, Wegovy, Ozempic
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
Forbes
Wed, 10/2/24 - 11:20 am
Tags:
weight loss, obesity, GLP-1 agonist, Ozempic, Wegovy, Novo Nordisk, Zepbound, Mounjaro, Eli Lilly
Patients sue over alleged stomach paralysis linked to Ozempic, Mounjaro
Beckers Hospital Review
Tue, 10/1/24 - 10:45 am
Tags:
legal, Novo Nordisk, Eli Lilly, Ozempic, Mounjaro, gastroparesis
Evotec and Novo Nordisk in technology development partnership
Reuters
Thu, 09/26/24 - 11:16 am
Tags:
Evotec, Novo Nordisk, stem cells
Ozempic linked to lower opioid overdose rate in those with diabetes, study shows
Stat
Wed, 09/25/24 - 12:04 pm
Tags:
Novo Nordisk, Ozempic, opioid addiction, Rybelsus, type 2 diabetes
With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
Fierce Pharma
Tue, 09/24/24 - 10:11 pm
Tags:
Senate, PBMs, Novo Nordisk, Pharma CEOs, drug pricing, Lars Fruergaard Jorgensen
Inside the GLP-1 'price war'
Beckers Hospital Review
Tue, 09/24/24 - 11:52 am
Tags:
GLP-1 agonists, obesity, weight loss, Eli Lilly, Novo Nordisk, Ozempic, Wegovy, Zepbound, Mounjaro, drug pricing
U.S. Senator Sanders says pharmacy middlemen commit to expanding weight-loss drug coverage if prices cut
Reuters
Tue, 09/24/24 - 11:40 am
Tags:
Bernie Sanders, PBMs, Novo Nordisk, Ozempic, Wegovy, drug pricing
Novo says Ozempic to be eligible for US price negotiations in less than a year
Reuters
Mon, 09/23/24 - 10:27 pm
Tags:
Novo Nordisk, Ozempic, drug pricing
Novo Nordisk faces US congressional grilling over price of weight loss drugs
Reuters
Mon, 09/23/24 - 09:49 am
Tags:
Novo Nordisk, Senate, Bernie Sanders, Ozempic, drug pricing
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
Fierce Biotech
Fri, 09/20/24 - 11:30 am
Tags:
Novo Nordisk, obesity, weight loss, clinical trials
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
Reuters
Thu, 09/19/24 - 09:16 pm
Tags:
Novo Nordisk, Wegovy, obesity, EMA, Europe, heart failure with preserved ejection fraction
Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver
Fierce Biotech
Wed, 09/18/24 - 01:23 pm
Tags:
Novo Nordisk, NanoVation Therapeutics, biobucks, genetic medicine
US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month
Reuters
Tue, 09/17/24 - 11:11 pm
Tags:
Bernie Sanders, generics, Novo Nordisk, drug pricing, Ozempic
Obesity pill race heats up as Novo, Roche and Terns share data
BioSpace
Tue, 09/17/24 - 11:22 am
Tags:
obesity, Novo Nordisk, Roche, Terns Pharmaceuticals, amycretin, TERN-601, CT-996, clinical trials
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Fierce Biotech
Wed, 09/11/24 - 11:53 am
Tags:
Novo Nordisk, obesity, clinical trials, amycretin
Study backs role of Novo Nordisk obesity drug in children
Pharmaphorum
Wed, 09/11/24 - 11:36 am
Tags:
Novo Nordisk, pediatrics, obesity, clinical trials, Saxenda

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.